InsiderClue
Stocks · Health care · Orthopedic, Prosthetic & Surgical Appliances & Supplies

REGENTIS BIOMATERIALS LTD.

RGNT Clue Score43
Israel Fiscal year ends December CIK 0001912966
$1.60 -5.88% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.60 −47.63% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 4 Dec 2025. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−1.9Net income−4.1EPS, diluted−24.09Fiscal year 2024Operating income0.9Net income4.8EPS, diluted1.72Fiscal year 2025Operating income−7.0Net income−13.6 −384.3%EPS, diluted−24.16
FY2023FY2024FY2025
Operating income −1.9 0.9 −7.0
Net income −4.1 4.8 −13.6
Growth −384.3%
EPS, diluted −24.09 1.72 −24.16

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flow
Fiscal year 2023Operating cash flow−1.2Fiscal year 2024Operating cash flow−0.6Fiscal year 2025Operating cash flow−1.4
FY2023FY2024FY2025
Operating cash flow −1.2 −0.6 −1.4

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Shareholders’ equity−45.9Fiscal year 2024Shareholders’ equity−41.1Fiscal year 2025Cash7.4Shareholders’ equity4.7
FY2023FY2024FY2025
Cash n/a n/a 7.4
Shareholders’ equity −45.9 −41.1 4.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Cash flow

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Operations
−1.2 −0.6 −1.4
Growth
Financing
0.3 0.5 8.5

Capital expenditure, dividends and buybacks are shown as money out, so negative.